Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC1 | P19801 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16317364 | 0.71 | AOC1 (0.50) | AOC1KDM4EBLMNPSR1CYP3A4 | |
| SCHEMBL10149598 | 0.71 | AOC1 (0.50) | AOC1KDM4EBLMNPSR1CYP3A4 | |
| SCHEMBL543476 | 0.70 | — | — | |
| SCHEMBL19059633 | 0.68 | KDM4E (0.55) | AOC1KDM4EBLMNPSR1CYP3A4 | |
| SCHEMBL4965314 | 0.68 | — | — | |
| SCHEMBL1997770 | 0.67 | — | — | |
| SCHEMBL5238058 | 0.67 | AOC1 (0.50) | AOC1KDM4EBLMNPSR1CYP3A4 | |
| SCHEMBL19558473 | 0.67 | AOC1 (0.46) | AOC1KDM4EBLMNPSR1CYP3A4 | |
| SCHEMBL9111778 | 0.67 | AOC1 (0.50) | AOC1KDM4EBLMNPSR1CYP3A4 | |
| SCHEMBL12425711 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786541-B2 | Inhibitor of sphingosine kinase 2 for treating Ebola | REDHILL BIOPHARMA LTD. (IL) | 2023-10-17 | — | — | US | disclosed |
| US-11786541-B2 | Inhibitor of sphingosine kinase 2 for treating Ebola | REDHILL BIOPHARMA LTD. (IL) | 2023-10-17 | — | — | US | disclosed |
| US-11633385-B2 | Combination compositions for treatment of cancer | REDHILL BIOPHARMA LTD. (IL) | 2023-04-25 | — | — | US | disclosed |
| US-20210369754-A1 | INHIBITOR OF SPHINGOSINE KINASE 2 FOR TREATING EBOLA | REDHILL BIOPHARMA LTD (IL) | 2021-12-02 | — | — | US | disclosed |
| US-11090325-B2 | Compositions for treating ebola virus infection | REDHILL BIOPHARMA LTD. (IL) | 2021-08-17 | — | — | US | disclosed |
| US-20210128538-A1 | COMBINATION COMPOSITIONS FOR TREATMENT OF CANCER | REDHILL BIOPHARMA LTD (IL) | 2021-05-06 | — | — | US | disclosed |
| US-10946000-B2 | Method for treating cancer with combination therapy | REDHILL BIOPHARMA LTD. (IL) | 2021-03-16 | — | — | US | disclosed |
| US-20200155585-A1 | COMPOSITIONS FOR TREATING EBOLA VIRUS INFECTION | REDHILL BIOPHARMA LTD (IL) | 2020-05-21 | — | — | US | disclosed |
| US-10543222-B2 | Therapy for inhibition of single-stranded RNA virus replication | REDHILL BIOPHARMA LTD. (IL) | 2020-01-28 | — | — | US | disclosed |
| US-10463654-B2 | Combination therapies for treating cancer | REDHILL BIOPHARMA LTD. (IL) | 2019-11-05 | — | — | US | disclosed |
| US-20180125831-A1 | COMBINATION THERAPIES FOR TREATING CANCER | REDHILL BIOPHARMA LTD (IL) | 2018-05-10 | — | — | US | disclosed |
| US-9844540-B2 | Combination therapies for treating cancer | REDHILL BIOPHARMA LTD. (IL) | 2017-12-19 | — | — | US | disclosed |
| US-20170095460-A1 | COMBINATION THERAPIES FOR TREATING CANCER | REDHILL BIOPHARMA LTD. (IL) | 2017-04-06 | — | — | US | disclosed |
| US-20160113954-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | REDHILL BIOPHARMA LTD. (IL) | 2016-04-28 | — | — | US | disclosed |
| US-8557800-B2 | Sphingosine kinase inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120095004-A1 | Sphingosine Kinase Inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
| US-8063248-B2 | 3-(4-Chloro-phenyl)-adamantane-1-carboxylic acidisopropylamide; antiproliferative, antiinflammatory agent, angiogenesis inhibitor; sphingolipid-derived signaling pathway; coupling acid or acylhalide of phenyl-adamantane derivatives with aminoalkyl-pyridine | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-7338961-B2 | Sphingosine kinase inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160113954-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | RNMT, EIF2AK2, POLRMT | AOC1 2897/4885KDM4E 2814/4885BLM 639/4885 |
| US-10543222-B2 | Therapy for inhibition of single-stranded RNA virus replication | RNMT, EIF2AK2, POLRMT | AOC1 2897/4885KDM4E 2814/4885BLM 639/4885 |
| US-20180125831-A1 | COMBINATION THERAPIES FOR TREATING CANCER | TPMT, KRAS, ACE | AOC1 981/4885KDM4E 376/4885BLM 3923/4885 |
| US-11786541-B2 | Inhibitor of sphingosine kinase 2 for treating Ebola | SPHK2, SPHK1, S1PR2 | AOC1 4348/4885KDM4E 2931/4885BLM 1710/4885 |
| US-20200155585-A1 | COMPOSITIONS FOR TREATING EBOLA VIRUS INFECTION | NEFM, EIF2AK2, IRF3 | AOC1 3793/4885KDM4E 4257/4885BLM 312/4885 |
| US-20120095004-A1 | Sphingosine Kinase Inhibitors | SPHK1, SPHK2, S1PR1 | AOC1 2917/4885KDM4E 2438/4885BLM 4398/4885 |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | SPHK1, SPHK2, S1PR2 | AOC1 3005/4885KDM4E 3842/4885BLM 4513/4885 |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | SPHK1, SPHK2, S1PR1 | AOC1 2917/4885KDM4E 2438/4885BLM 4398/4885 |
| US-10946000-B2 | Method for treating cancer with combination therapy | TPMT, KRAS, SDHA | AOC1 467/4885KDM4E 290/4885BLM 3598/4885 |
| US-11633385-B2 | Combination compositions for treatment of cancer | KRAS, TPMT, CYP2D6 | AOC1 1080/4885KDM4E 445/4885BLM 3514/4885 |
| US-20210128538-A1 | COMBINATION COMPOSITIONS FOR TREATMENT OF CANCER | KRAS, TPMT, CYP2D6 | AOC1 1080/4885KDM4E 445/4885BLM 3514/4885 |
| US-20170095460-A1 | COMBINATION THERAPIES FOR TREATING CANCER | KRAS, ACE, TPMT | AOC1 1111/4885KDM4E 293/4885BLM 3840/4885 |
| US-20210369754-A1 | INHIBITOR OF SPHINGOSINE KINASE 2 FOR TREATING EBOLA | SPHK2, SPHK1, S1PR2 | AOC1 4348/4885KDM4E 2931/4885BLM 1710/4885 |
| US-10463654-B2 | Combination therapies for treating cancer | TPMT, KRAS, ACE | AOC1 981/4885KDM4E 376/4885BLM 3923/4885 |
| US-11090325-B2 | Compositions for treating ebola virus infection | NEFM, EIF2AK2, IRF3 | AOC1 3793/4885KDM4E 4257/4885BLM 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.